A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines

Virology

Volumn 424, Issue 2, 2012, Pages 129-137

  Hughes, Holly R ^a   Crill, Wayne D ^a   Davis, Brent S ^a   Chang, Gwong Jen J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Adjuvant; Flavivirus; T cell epitope; Transmembrane domain; Vaccine

Indexed keywords

DENGUE VACCINE; EPITOPE;

ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL INTERACTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; FLOW CYTOMETRY; IMMUNOGENICITY; MICROBIAL KINETICS; MORPHOLOGY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; UPREGULATION; VIRUS PARTICLE; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; EPITOPES, T-LYMPHOCYTE; HUMANS; MICE; MICE, INBRED C57BL; VACCINATION; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

ARBOVIRUS; DENGUE VIRUS; FLAVIVIRUS; MUS; WEST NILE VIRUS;

EID: 84857034408     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.12.012     Document Type: Article

References (39)

1. Armali Z., Ramadan R., Chlebowski A., Azzam Z.S. West Nile meningo-encephalitis infection in a kidney transplant recipient. Transplant. Proc. 2003, 35:2935-2936.
2. Barshes N.R., Agee E.E., Zgabay T., Brunicardi F.C., Goss J.A., DeBakey M.E. West Nile Virus encephalopathy following pancreatic islet transplantation. Am. J. Transplant. 2006, 6:3037.
3. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., Koup R.A., Picker L.J. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 2001, 75:11983-11991.
4. Brien J.D., Uhrlaub J.L., Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur. J. Immunol. 2007, 37:1855-1863.
5. CDC Locally acquired dengue- Key West, Florida, 2009-2010. MMWR 2010, 577-581.
6. Chang G.J., Hunt A.R., Davis B. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J. Virol. 2000, 74:4244-4252.
7. Chang G.J., Hunt A.R., Holmes D.A., Springfield T., Chiueh T.S., Roehrig J.T., Gubler D.J. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 2003, 306:170-180.
8. Chang G.J., Davis B.S., Stringfield C., Lutz C. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection. Vaccine 2007, 25:2325-2330.
9. Chen D., Edgtton K., Gould A., Guo H., Mather M., Haigh O., Cochrane M., Kattenbelt J., Thomson S., Tindle R. HBsAg-vectored vaccines simultaneously deliver CTL responses to protective epitopes from multiple viral pathogens. Virology 2010, 398:68-78.
10. Chiarella P., Massi E., De Robertis M., Fazio V.M., Signori E. Strategies for effective naked-DNA vaccination against infectious diseases. Recent Pat. Antiinfect. Drug Discov. 2008, 3:93-101.
11. Clark L.B., Foy T.M., Noelle R.J. CD40 and its ligand. Adv. Immunol. 1996, 63:43-78.
12. Crill W.D., Hughes H.R., Delorey M.J., Chang G.J. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 2009, 4:e4991.
13. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: A review. Vaccine 2010, 28:5513-5523.
14. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., Bowen R., Bunning M.L. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 2001, 75:4040-4047.
15. del Guercio M.F., Alexander J., Kubo R.T., Arrhenius T., Maewal A., Appella E., Hoffman S.L., Jones T., Valmori D., Sakaguchi K., Grey H.M., Sette A. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997, 15:441-448.
16. DeSalvo D., Roy-Chaudhury P., Peddi R., Merchen T., Konijetti K., Gupta M., Boardman R., Rogers C., Buell J., Hanaway M., Broderick J., Smith R., Woodle E.S. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation 2004, 77:466-469.
17. Ferguson D.D., Gershman K., LeBailly A., Petersen L.R. Characteristics of the rash associated with West Nile virus fever. Clin. Infect. Dis. 2005, 41:1204-1207.
18. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 1998, 16:111-135.
19. Gubler D.J. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 2002, 33:330-342.
20. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., Jourdier T.M., Ramirez L., Gregoire V., Charnay C., Burdin N., Dumas R., Lang J. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am.J.Trop. Med. Hyg. 2009, 80:302-311.
21. Hoffmeister B., Kiecker F., Tesfa L., Volk H.D., Picker L.J., Kern F. Mapping T cell epitopes by flow cytometry. Methods 2003, 29:270-281.
22. Kern F., Faulhaber N., Frommel C., Khatamzas E., Prosch S., Schonemann C., Kretzschmar I., Volkmer-Engert R., Volk H.D., Reinke P. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 2000, 30:1676-1682.
23. King C.A., Spellerberg M.B., Zhu D., Rice J., Sahota S.S., Thompsett A.R., Hamblin T.J., Radl J., Stevenson F.K. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 1998, 4:1281-1286.
24. Kleinschmidt-DeMasters B.K., Marder B.A., Levi M.E., Laird S.P., McNutt J.T., Escott E.J., Everson G.T., Tyler K.L. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch. Neurol. 2004, 61:1210-1220.
25. Kumar D., Prasad G.V., Zaltzman J., Levy G.A., Humar A. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004, 77:399-402.
26. Leitner W.W., Ying H., Restifo N.P. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999, 18:765-777.
27. Lu Y., Ouyang K., Fang J., Zhang H., Wu G., Ma Y., Zhang Y., Hu X., Jin L., Cao R., Fan H., Li T., Liu J. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine 2009, 27:5411-5418.
28. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., Persaud N., Trigona W., Fu T.M., Sinclair E., Bredt B.M., McCune J.M., Maino V.C., Kern F., Picker L.J. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 2001, 255:27-40.
29. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., Andrews C.A., Xu Q., Davis B.S., Nason M., Fay M., Koup R.A., Roederer M., Bailer R.T., Gomez P.L., Mascola J.R., Chang G.J., Nabel G.J., Graham B.S. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 2007, 196:1732-1740.
30. Mor G. Plasmid DNA: a new era in vaccinology. Biochem. Pharmacol. 1998, 55:1151-1153.
31. n.a. Investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb. Mortal. Wkly. Rep. 2002, 51:973-974.
32. n.a. Update: Investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion. MMWR Morb. Mortal. Wkly. Rep. 2002, 51:833-836.
33. n.a. West Nile virus infection in organ donor and transplant recipients--Georgia and Florida. MMWR Morb. Mortal. Wkly. Rep. 2002, 51:790.
34. Rothman A.L., Kurane I., Ennis F.A. Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J. Virol. 1996, 70:6540-6546.
35. Sangkawibha N., Rojanasuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., Phanthumachinda B., Halstead S.B. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 1984, 120:653-669.
36. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356:152-154.
37. Weiskopf D., Yauch L.E., Angelo M.A., John D.V., Greenbaum J.A., Sidney J., Kolla R.V., De Silva A.D., de Silva A.M., Grey H., Peters B., Shresta S., Sette A. Insights into HLA-Restricted T Cell Responses in a Novel Mouse Model of Dengue Virus Infection Point toward New Implications for Vaccine Design. J. Immunol. 2011, 187:4268-4279.
38. Zhang T., Xu Y., Qiao L., Wang Y., Wu X., Fan D., Peng Q., Xu X. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 2010, 28:3479-3487.
39. Zhu D., Williams J.N., Rice J., Stevenson F.K., Heckels J.E., Christodoulides M. A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis. Infect. Immun. 2008, 76:334-338.